Lower-risk cannabis use guidelines: A comprehensive update of evidence and recommendations

American Journal of Public Health

Volumn 107, Issue 8, 2017, Pages e1-e12

  Fischer, Benedikt ^a   Russell, Cayley ^a   Sabioni, Pamela ^a   Van Den Brink, Wim ^b   Le Foll, Bernard ^c   Hall, Wayne ^d   Rehm, Jürgen ^a   Room, Robin ^e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e LA TROBE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS;

CANNABIS SMOKING; EVIDENCE BASED MEDICINE; HUMAN; PUBLIC HEALTH; RISK ASSESSMENT;

CANNABIS; EVIDENCE-BASED MEDICINE; HUMANS; MARIJUANA SMOKING; PUBLIC HEALTH; RISK ASSESSMENT;

EID: 85024392322     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2017.303818     Document Type: Review

References (224)

1. World Drug Report 2015. Vienna, Austria: United Nations Office on Drugs and Crime; 2015.
2. Degenhardt L, Ferrari AJ, Calabria B, et al. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 Study [correction in PLoS One. 2016;11(10): e0165221]. PLoS One. 2013;8(10):e76635.
3. Canadian Alcohol and Drug Use Monitoring Survey (CADUMS): Summary of Results for 2012. Ottawa, ON: Health Canada; 2014.
4. Volkow ND, Baler RD, Compton WM, Weiss SRB. Adverse health effects of marijuana use. N Engl J Med. 2014;370(23):2219-2227.
5. Hall W, Degenhardt L. Adverse health effects of nonmedical cannabis use. Lancet. 2009;374(9698):1383-1391.
6. The health and social effects of nonmedical cannabis use. Geneva, Switzerland: World Health Organization; 2016.
7. National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: TheCurrent State ofEvidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017.
8. Rogeberg O, Elvik R. The effects of cannabis intoxication on motor vehicle collision revisited and revised. Addiction. 2016;111(8):1348-1359.
9. Broyd SJ, van Hell HH, Beale C, Yucel M, Solowij N. Acute and chronic effects of cannabinoids on human cognition-a systematic review. Biol Psychiatry. 2016; 79(7):557-567.
10. Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016;42(5):1262-1269.
11. Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA. Effects of marijuana smoking on pulmonary function and respiratory complications. Arch Intern Med. 2007;167(3):221-228.
12. Gunn JK, Rosales CB, Center KE, et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open. 2016;6(4):e009986.
13. Rubino T, Parolaro D. Long lasting consequences of cannabis exposure in adolescence. Mol Cell Endocrinol. 2008;286(1-2 suppl 1):S108-S113.
14. Jager G, Ramsey NF. Long-term consequences of adolescent cannabis exposure on the development of cognition, brain structure and function: an overview of animal and human research. Curr Drug Abuse Rev. 2008; 1(2):114-123.
15. Bava S, Tapert SF. Adolescent brain development and the risk for alcohol and other drug problems. Neuropsychol Rev. 2010;20(4):398-413.
16. Macleod J, Oakes R, Copello A, et al. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet. 2004;363(9421):1579-1588.
17. Fergusson DM, Boden JM. Cannabis use and later life outcomes. Addiction. 2008;103(6):969-976.
18. Degenhardt L, Whiteford HA, Ferrari AJ, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1564-1574.
19. Imtiaz S, Shield KD, Roerecke M, et al. The burden of disease attributable to cannabis use in Canada in 2012. Addiction. 2016;111(4):653-662.
20. Fischer B, Imtiaz S, Rudzinski K, Rehm J. Crude estimates of cannabis-attributable mortality and morbidity in Canada-implications for public health focused intervention priorities. J Public Health (Oxf). 2016;38(1):183-188.
21. Fischer B, Ala-Leppilampi K, Single E, Robins A. Cannabis law reform in Canada: is the "saga of promise, hesitation and retreat" coming to an end? Can J Criminol Crim Justice. 2003;45(3):265-298.
22. Room R, Fischer B, Hall W, Lenton S, Reuter P. Cannabis Policy: Moving Beyond Stalemate.New York, NY: Oxford University Press; 2010.
23. Pardo B. Cannabis policy reforms in the Americas: a comparative analysis of Colorado, Washington, and Uruguay. Int J Drug Policy. 2014;25(4):727-735.
24. Room R. Legalising a market for cannabis for pleasure: Colorado, Washington, Uruguay and beyond. Addiction. 2014;109(3):345-351.
25. Hall W, Weier M. Assessing the public health impacts of legalizing recreational cannabis use in the USA. Clin Pharmacol Ther. 2015;97(6):607-615.
26. Blickman T. Cannabis Policy Reform in Europe: Bottom Up Rather Than TopDown. Amsterdam, The Netherlands: Transnational Institute; 2014.
27. Rehm J, Fischer B. Cannabis legalization with strict regulation, the overall superior policy option for public health. Clin Pharmacol Ther. 2015;97(6):541-544.
28. Task Force on Cannabis Legalization and Regulation. A Framework for the Legalization and Regulation of Cannabis in Canada: The Final Report of the Task Force on Cannabis Legalization and Regulation. Ottawa, ON: Health Canada; 2016.
29. Bondy SJ, Rehm J, Ashley MJ, Walsh G, Single E, Room R. Low-risk drinking guidelines: the scientific evidence. Can J Public Health. 1999;90(4):264-270.
30. Rehm J, Patra J. Different guidelines for different countries? On the scientific basis of low-risk drinking guidelines and their implications. Drug Alcohol Rev. 2012; 31(2):156-161.
31. Global Recommendations on Physical Activity for Health. Geneva, Switzerland: World Health Organization; 2010.
32. King JC,Dietary Guidelines Advisory Committee. An evidence-based approach for establishing dietary guidelines. J Nutr. 2007;137(2):480-483.
33. Kirby DB. The impact of abstinence and comprehensive sex and STD/HIV education programs on adolescent sexual behavior. SexRes Soc Policy. 2008;5(3):18-27.
34. Hoelscher DM, Evans A, Parcel GS, Kelder SH. Designing effective nutrition interventions for adolescents. J Am Diet Assoc. 2002;102(3, suppl):S52-S63.
35. Snyder LB. Health communication campaigns and their impact on behavior. J Nutr Educ Behav. 2007;39(2, suppl):S32-S40.
36. Fischer B, Jeffries V, Hall W, Room R, Goldner E, Rehm J. Lower Risk Cannabis UseGuidelines for Canada (LRCUG): a narrative review of evidence and recommendations. Can J Public Health. 2011;102(5):324-327.
37. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097.
38. Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ. 2008;336(7652): 1049-1051.
39. From evidence to recommendations: transparent and sensible. GRADE Working Group. 2017. Available at: http://www.gradeworkinggroup.org. Accessed December 21, 2016.
40. Committee on Standards for DevelopingTrustworthy Clinical Practice Guidelines. Current best practices and standards for development of trustworthy CPGs: Part II, traversing the process. In: Graham R, MancherM,Miller WolmanD,Greenfield S, Steinberg E, eds. Clinical Practice Guidelines We Can Trust. Washington, DC: National Academies Press; 2011: 134-169.
41. Eccles M, Clapp Z, Grimshaw J, et al. North of England Evidence Based Guidelines Development Project: methods of guideline development. BMJ. 1996; 312(7033):760-762.
42. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ. 1999; 318(7183):593-596.
43. Jacobus J, Tapert SF. Effects of cannabis on the adolescent brain. Curr Pharm Des. 2014;20(13): 2186-2193.
44. Lisdahl KM,Gilbart ER, WrightNE, Shollenbarger S. Dare to delay? The impacts of adolescent alcohol and marijuana use onset on cognition, brain structure, and function. Front Psychiatry. 2013;4:53.
45. Volkow ND, Swanson JM, Evins AE, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry. 2016;73(3):292-297.
46. James A, James C, Thwaites T. The brain effects of cannabis in healthy adolescents and in adolescents with schizophrenia: a systematic review. Psychiatry Res Neuroimaging. 2013;214(3):181-189.
47. Lopez-Larson MP, Bogorodzki P, Rogowska J, et al. Altered prefrontal and insular cortical thickness in adolescent marijuana users. Behav Brain Res. 2011;220(1): 164-172.
48. Jacobus J, Squeglia LM, Sorg SF, Nguyen-Louie TT, Tapert SF. Cortical thickness and neurocognition in adolescent marijuana and alcohol users following 28 days of monitored abstinence. J Stud Alcohol Drugs. 2014; 75(5):729-743.
49. Cookey J, Bernier D, Tibbo PG. White matter changes in early phase schizophrenia and cannabis use: an update and systematic review of diffusion tensor imaging studies. Schizophr Res. 2014;156(2-3):137-142.
50. Camchong J, Lim KO, Kumra S. Adverse effects of cannabis on adolescent brain development: a longitudinal study. Cereb Cortex. 2017;27(3):1922-1930.
51. Gruber SA, Dahlgren MK, Sagar KA, Gonenc A, Lukas SE. Worth the wait: effects of age of onset of marijuana use on white matter and impulsivity. Psychopharmacology (Berl). 2014;231(8):1455-1465.
52. Schlossarek S, Kempkensteffen J, Reimer J, Verthein U. Psychosocial determinants of cannabis dependence: a systematic review of the literature. Eur Addict Res. 2016; 22(3):131-144.
53. Malchow B, Hasan A, Fusar-Poli P, Schmitt A, Falkai P, Wobrock T. Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. EurArch Psychiatry Clin Neurosci. 2013;263(1):3-13.
54. Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol. 2005;19(2):187-194.
55. Gruber SA, Sagar KA, Dahlgren MK, Racine M, Lukas SE. Age of onset of marijuana use and executive function. Psychol Addict Behav. 2012;26(3):496-506.
56. Anthony J. The epidemiology of cannabis dependence. In: Roffman R, Stephens R, eds. Cannabis Dependence: Its Nature, Consequences and Treatment. Cambridge, UK: Cambridge University Press; 2006.
57. Fontes MA, Bolla KI, Cunha PJ, et al. Cannabis use before age 15 and subsequent executive functioning. Br J Psychiatry. 2011;198(6):442-447.
58. Solowij N, Jones KA, Rozman ME, et al. Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. Psychopharmacology (Berl). 2011; 216(1):131-144.
59. Rey JM, SawyerMG,Raphael B, PattonGC, Lynskey MT.Mental health of teenagerswho use cannabis: results of an Australian survey. Br J Psychiatry. 2002;180:216-221.
60. Fergusson DM, Horwood LJ, Ridder EM. Tests of causal linkages between cannabis use and psychotic symptoms. Addiction. 2005;100(3):354-366.
61. CaspiA,Moffitt TE,CannonM, et al.Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene ? environment interaction. Biol Psychiatry. 2005;57(10):1117-1127.
62. McLaren JA, Silins E, Hutchinson D, Mattick RP, Hall W. Assessing evidence for a causal link between cannabis and psychosis: a review of cohort studies. Int J Drug Policy. 2010;21(1):10-19.
63. Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A. 2012; 109(40):E2657-E2664.
64. McGrath J, Welham J, Scott J, et al. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry. 2010;67(5):440-447.
65. Le Strat Y, Dubertret C, Le Foll B. Impact of age at onset of cannabis use on cannabis dependence and driving under the influence in the United States. Accid Anal Prev. 2015;76:1-5.
66. Lynskey MT, Heath AC, Bucholz KK, et al. Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA. 2003;289(4):427-433.
67. Grant JD, Lynskey MT, Scherrer JF, Agrawal A, Heath AC, Bucholz KK. A cotwin-control analysis of drug use and abuse/dependence risk associated with early-onset cannabis use. Addict Behav. 2010;35(1):35-41.
68. Horwood LJ, Fergusson DM, Hayatbakhsh MR, et al. Cannabis use and educational achievement: findings from three Australasian cohort studies. Drug Alcohol Depend. 2010;110(3):247-253.
69. Lynskey MT, Coffey C, Degenhardt L, Carlin JB, Patton G. A longitudinal study of the effects of adolescent cannabis use on high school completion. Addiction. 2003; 98(5):685-692.
70. Cascini F, Aiello C, Di Tanna G. Increasing delta-9-tetrahydrocannabinol (delta-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev. 2012;5(1):32-40.
71. Stogner JM, Miller BL. Assessing the dangers of "dabbing": mere marijuana or harmful new trend? Pediatrics. 2015;136(1):1-3.
72. Pijlman FT, Rigter SM, Hoek J, Goldschmidt HM, Niesink RJ. Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addict Biol. 2005;10(2):171-180.
73. Swift W, Wong A, Li KM, Arnold JC,McGregor IS. Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PLoS One. 2013;8(7): e70052.
74. Mehmedic Z, Chandra S, Slade D, et al. Potency trends of delta9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci. 2010;55(5):1209-1217.
75. Hall W, Degenhardt L. High potency cannabis: a risk factor for dependence, poor psychosocial outcomes, and psychosis. BMJ. 2015;350:h1205.
76. Freeman TP,Winstock AR. Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med. 2015;45(15): 3181-3189.
77. Di Forti M, Marconi A, Carra E, et al. Proportion of patients in South London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry. 2015;2(3):233-238.
78. Pierre JM, Gandal M, Son M. Cannabis-induced psychosis associated with high potency "wax dabs." Schizophr Res. 2016;172(1-3):211-212.
79. Hunault CC, Mensinga TT, Bocker KB, et al. Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC). Psychopharmacology (Berl). 2009;204(1):85-94.
80. van der Pol P, Liebregts N, Brunt T, et al. Crosssectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. Addiction. 2014;109(7):1101-1109.
81. Freeman TP, MorganCJ, Hindocha C, Schafer G, Das RK, Curran HV. Just say "know": how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints? Addiction. 2014;109(10):1686-1694.
82. Batalla A, Crippa JA, Busatto GF, et al. Neuroimaging studies of acute effects of THC and CBD in humans and animals: a systematic review. Curr Pharm Des. 2014; 20(13):2168-2185.
83. Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010;35(3):764-774.
84. Martin-Santos R, Crippa JA, Batalla A, et al. Acute effects of a single, oral dose of D9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr Pharm Des. 2012;18(32):4966-4979.
85. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol-recent advances. Chem Biodivers. 2007;4(8):1678-1692.
86. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006;66(2): 234-246.
87. Iseger TA, Bossong MG. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res. 2015;162(1-3):153-161.
88. Englund A, Morrison PD, Nottage J, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol. 2013;27(1):19-27.
89. Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry. 2008;192(4):306-307.
90. Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL,Kahn RS, Boks MP. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res. 2011;130(1-3):216-221.
91. Zhornitsky S, Potvin S. Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals (Basel). 2012; 5(5):529-552.
92. Harris CR, Brown A. Synthetic cannabinoid intoxication: a case series and review. J Emerg Med. 2013; 44(2):360-366.
93. SeelyKA, Lapoint J,Moran JH, Fattore L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39(2):234-243.
94. van Amsterdam J, Brunt T, van den Brink W. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol. 2015;29(3):254-263.
95. Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila). 2016;54(1):1-13.
96. Castaneto MS,Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014;144:12-41.
97. Gunderson EW, Haughey HM, AitDaoud N, Joshi AS, Hart CL. "Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict. 2012;21(4):320-326.
98. Bush DM, Woodwell DA. Update: drug-related emergency department visits involving synthetic cannabinoids. TheCBHSQReport. Rockville, MD;Substance Abuse and Mental Health Services Administration; 2013.
99. Law R, Schier J, Martin C, Chang A, Wolkin A, Centers for Disease Control and Prevention. Notes from the field: increase in reported adverse health effects related to synthetic cannabinoid use-United States, January-May 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22): 618-619.
100. Winstock AR, Barratt MJ. The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Hum Psychopharmacol. 2013;28(4):390-393.
101. Murphy F, Sales P, Murphy S, Averill S, LauN, Sato S. Baby boomers and cannabis delivery systems. J Drug Issues. 2015;45(3):293-313.
102. Ialomiteanu AR, Hamilton H, Adlaf E, Mann RE. CAMH Monitor eReport 2015: Substance use, mental health and well-being among Ontario adults. Toronto, ON: Centre for Addiction and Mental Health; 2016.
103. Agrawal A, Budney AJ, Lynskey MT. The co-occurring use and misuse of cannabis and tobacco: a review. Addiction. 2012;107(7):1221-1233.
104. Tashkin DP. Increasing cannabis use: what we still need to know about its effects on the lung. Respirology. 2014;19(5):619-620.
105. Gates P, Jaffe A, Copeland J. Cannabis smoking and respiratory health: consideration of the literature. Respirology. 2014;19(5):655-662.
106. Lee MH, HancoxRJ. Effects of smoking cannabis on lung function. Expert Rev Respir Med. 2011;5(4):537-546.
107. Pletcher MJ, Vittinghoff E, Kalhan R, et al. Association between marijuana exposure and pulmonary function over 20 years. JAMA. 2012;307(2):173-181.
108. Martinasek MP, McGrogan JB, Maysonet A. A systematic review of the respiratory effects of inhalational marijuana. Respir Care. 2016;61(11):1543-1551.
109. Tashkin DP, Simmons MS, Tseng CH. Impact of changes in regular use of marijuana and/or tobacco on chronic bronchitis. COPD. 2012;9(4):367-374.
110. Hancox RJ, Shin HH, Gray AR, Poulton R, Sears MR. Effects of quitting cannabis on respiratory symptoms. Eur Respir J. 2015;46(1):80-87.
111. Fiorelli A, Accardo M, Vicidomini G, Messina G, Laperuta P, Santini M. Does cannabis smoking predispose to lung bulla formation? Asian Cardiovasc Thorac Ann. 2014;22(1):65-71.
112. Bouti K, Borki R, Fenane H, Harrak L. Cannabis smoking and risk of lung cancer: a systematic review and meta-analysis. Int J Med Surg. 2014;1(2):3-9.
113. Hashibe M, Straif K, Tashkin DP, Morgenstern H, Greenland S, Zhang ZF. Epidemiologic review of marijuana use and cancer risk: a systematic review. Alcohol. 2005;35(3):265-275.
114. Zhang LR, Morgenstern H, Greenland S, et al. Cannabis smoking and lung cancer risk: pooled analysis in the International Lung Cancer Consortium. Int J Cancer. 2015;136(4):894-903.
115. Grotenhermen F. Harm reduction associated with inhalation and oral administration of cannabis and THC. J Cannabis Therapeutics. 2001;1(3):133-152.
116. Lutchmansingh D, Pawar L, Savici D. Legalizing cannabis: a physician's primer on the pulmonary effects of marijuana. Curr Respir Care Rep. 2014;3(4):200-205.
117. Swift W, Copeland J, Lenton S. Cannabis and harm reduction. Drug Alcohol Rev. 2000;19:101-112.
118. Tashkin DP. Effects of cannabis on the respiratory system. In: Kalant H, CorrigallW, Hall W, Smart R, eds. The Health Effects of Cannabis. Toronto, ON: Addiction Research Foundation; 1999.
119. Thu K, Hayes M, Miles S, Tierney L, Foy A. Marijuana "bong" smoking and tuberculosis. Intern Med J. 2013;43(4):456-458.
120. Cozzi NV. Effects of water filtration on marijuana smoke: a literature review. MAPS Bull. 1993;4(2):4-6.
121. Gieringer DH. Cannabis vaporization: a promising strategy for smoke harm reduction. J Cannabis Ther. 2001; 1(3-4):153-170.
122. Gieringer D, St. Laurent J, Goodrich S. Cannabis vaporizer combines efficient delivery of THC with effective suppression of pryolytic compounds. J Cannabis Ther. 2004;4(1):7-27.
123. Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R. Evaluation of a vaporizing device (volcano) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci. 2006;95(6):1308-1317.
124. Earleywine M, VanDamNT.Case studies in cannabis vaporization. Addict Res Theory. 2010;18(3):243-249.
125. Van Dam NT, Earleywine M. Pulmonary function in cannabis users: support for a clinical trial of the vaporizer. Int J Drug Policy. 2010;21(6):511-513.
126. Loflin M, Earleywine M.No smoke, no fire:what the initial literature suggests regarding vapourized cannabis and respiratory risk. Can J Respir Ther. 2015;51(1):7-9.
127. Jensen RP, Luo W, Pankow JF, Strongin RM, Peyton DH. Hidden formaldehyde in e-cigarette aerosols. N Engl J Med. 2015;372(4):392-394.
128. Monte AA, Zane RD, Heard KJ.The implications of marijuana legalization in Colorado. JAMA. 2015;313(3): 241-242.
129. Loflin M, Earleywine M. A new method of cannabis ingestion: the dangers of dabs? Addict Behav. 2014;39(10): 1430-1433.
130. Wang GS, Roosevelt G, Le Lait MC, et al. Association of unintentional pediatric exposures with decriminalization of marijuana in the United States. Ann Emerg Med. 2014;63(6):684-689.
131. Wang GS, Roosevelt G, Heard K. Pediatric marijuana exposures in a medical marijuana state. JAMA Pediatr. 2013;167(7):630-633.
132. Wang GS, Le Lait MC, Deakyne SJ, Bronstein AC, Bajaj L, Roosevelt G. Unintentional pediatric exposures to marijuana in Colorado, 2009-2015. JAMA Pediatr. 2016;170(9):e160971.
133. SolowijN, Lorenzetti V, Yucel M. Effects of cannabis use onhuman behavior: a call for standardization of cannabis use metrics. JAMA Psychiatry. 2016;73(9):995-996.
134. Results From the 2013 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014.
135. Gibbs M, Winsper C, Marwaha S,Gilbert E, Broome M, Singh SP. Cannabis use and mania symptoms: a systematic review and meta-analysis. J Affect Disord. 2015; 171:39-47.
136. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007; 370(9584):319-328.
137. Reece AS. Chronic toxicology of cannabis. Clin Toxicol (Phila). 2009;47(6):517-524.
138. Elvik R. Risk of road accident associated with the use of drugs: a systematic review and meta-analysis of evidence from epidemiological studies. Accid Anal Prev. 2013; 60:254-267.
139. Borges G, Bagge CL, Orozco R. A literature review and meta-analyses of cannabis use and suicidality. J Affect Disord. 2016;195:63-74.
140. Lorenzetti V, Lubman DI, Whittle S, Solowij N, Yucel M. Structural MRI findings in long-term cannabis users: what do we know? Subst Use Misuse. 2010;45(11): 1787-1808.
141. Ganzer F, Broning S, Kraft S, Sack P, Thomasius R. Weighing the evidence: a systematic review on long-term neurocognitive effects of cannabis use in abstinent adolescents and adults. Neuropsychol Rev. 2016;26(2): 186-222.
142. Batalla A, Bhattacharyya S, Yucel M, et al. Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PLoS One. 2013;8(2):e55821.
143. Battistella G, Fornari E, Annoni JM, et al. Longterm effects of cannabis on brain structure. Neuropsychopharmacology. 2014;39(9):2041-2048.
144. Cousijn J, Wiers RW, Ridderinkhof KR, van den Brink W, Veltman DJ, Goudriaan AE. Grey matter alterations associated with cannabis use: results of a VBM study in heavy cannabis users and healthy controls. Neuroimage. 2012;59(4):3845-3851.
145. Lorenzetti V, Solowij N, Whittle S, et al. Gross morphological brain changes with chronic, heavy cannabis use. Br J Psychiatry. 2015;206(1):77-78.
146. Yücel M, Lorenzetti V, Suo C, et al. Hippocampal harms, protection and recovery following regular cannabis use. Transl Psychiatry. 2016;6:e710.
147. Crean RD, Crane NA, Mason BJ. An evidencebased review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med. 2011; 5(1):1-8.
148. Ramaekers JG, van Wel JH, Spronk DB, et al. Cannabis and tolerance: acute drug impairment as a function of cannabis use history. Sci Rep. 2016;6: 26843.
149. Schwope DM, Bosker WM, Ramaekers JG, Gorelick DA, Huestis MA. Psychomotor performance, subjective and physiological effects and whole blood delta (9)-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis. J Anal Toxicol. 2012;36(6):405-412.
150. Andrasson S, Allebeck P, Rydberg U. Schizophrenia in users and nonusers of cannabis. A longitudinal study in Stockholm County. Acta Psychiatr Scand. 1989; 79(5):505-510.
151. Stefanis NC, Delespaul P, Henquet C, Bakoula C, StefanisCN,Van Os J. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction. 2004;99(10):1333-1341.
152. Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychol Med. 2003;33(1):15-21.
153. Henquet C, Krabbendam L, de Graaf R, ten Have M, vanOs J.Cannabis use and expression ofmania in the general population. J Affect Disord. 2006;95(1-3): 103-110.
154. Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med. 2014; 44(4):797-810.
155. van Ours JC, Williams J, Fergusson D, Horwood LJ. Cannabis use and suicidal ideation. J Health Econ. 2013; 32(3):524-537.
156. Degenhardt L, Coffey C, Romaniuk H, et al. The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction. 2013;108(1):124-133.
157. Coffey C, Carlin JB, Degenhardt L, Lynskey M, Sanci L, Patton GC. Cannabis dependence in young adults: an Australian population study. Addiction. 2002; 97(2):187-194.
158. van der Pol P, Liebregts N, de Graaf R, Korf DJ, van den Brink W, van Laar M. Predicting the transition from frequent cannabis use to cannabis dependence: a threeyear prospective study. Drug Alcohol Depend. 2013;133(2): 352-359.
159. Silins E,Horwood LJ, Patton GC, et al. Young adult sequelae of adolescent cannabis use: an integrative analysis. Lancet Psychiatry. 2014;1(4):286-293.
160. Swift W, Coffey C, Degenhardt L, Carlin JB, Romaniuk H, Patton GC. Cannabis and progression to other substance use in young adults: findings from a 13-year prospective population-based study. J Epidemiol Community Health. 2012;66(7):e26.
161. Patton GC, Coffey C, Lynskey MT, et al. Trajectories of adolescent alcohol and cannabis use into young adulthood. Addiction. 2007;102(4):607-615.
162. Hall WD, Lynskey M. Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. Drug Alcohol Rev. 2005;24(1):39-48.
163. Li MC, Brady JE, DiMaggio CJ, Lusardi AR, Tzong KY, Li G. Marijuana use and motor vehicle crashes. Epidemiol Rev. 2012;34(1):65-72.
164. Hartman RL, Huestis MA. Cannabis effects on driving skills. Clin Chem. 2013;59(3):478-492.
165. Zeisser C, Thompson K, Stockwell T, et al. A "standard joint"? The role of quantity in predicting cannabis-related problems. Addict Res Theory. 2012;20(1): 82-92.
166. Armentano P. Cannabis and psychomotor performance: a rational review of the evidence and implications for public policy. Drug Test Anal. 2013;5(1):52-56.
167. Ranganathan M, D'Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl). 2006;188(4):425-444.
168. Sharma P, Murthy P, Bharath MM. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry. 2012;7(4):149-156.
169. Lee D, Bergamaschi MM, Milman G, et al. Plasma cannabinoid pharmacokinetics after controlled smoking and ad libitum cannabis smoking in chronic frequent users. J Anal Toxicol. 2015;39(8):580-587.
170. Battistella G, Fornari E, Thomas A, et al. Weed or wheel! FMRI, behavioural, and toxicological investigations of how cannabis smoking affects skills necessary for driving. PLoS One. 2013;8(1):e52545.
171. Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schneider E, MoellerMR. High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology. 2006;31(10):2296-2303.
172. Hartman RL, Brown TL, Milavetz G, et al. Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships. Drug Test Anal. 2016;8(7):690-701.
173. Hartman RL, Brown TL, Milavetz G, et al. Effect of blood collection time on measured delta9-tetrahydrocannabinol concentrations: implications for driving interpretation and drug policy. Clin Chem. 2016; 62(2):367-377.
174. Hunault CC, Bocker KB, Stellato RK,Kenemans JL, de Vries I, Meulenbelt J. Acute subjective effects after smoking joints containing up to 69 mg delta9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial. Psychopharmacology (Berl). 2014; 231(24):4723-4733.
175. NHTSA releases two new studies on impaired driving on US roads: drunk driving declines while drug use behind the wheel rises. Washington, DC: National Highway Traffic Safety Administration; 2015.
176. Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and metaanalysis. BMJ. 2012;344:e536.
177. Asbridge M, Mann R, Cusimano MD, et al. Cannabis and traffic collision risk: findings from a case-crossover study of injured drivers presenting to emergency departments. Int J Public Health. 2014;59(2):395-404.
178. Ronen A, Chassidim HS, Gershon P, et al. The effect of alcohol, THC and their combination on perceived effects, willingness to drive and performance of driving and non-driving tasks. Accid Anal Prev. 2010;42(6):1855-1865.
179. Hartman RL, Brown TL, Milavetz G, et al. Cannabis effects on driving lateral control with and without alcohol. Drug Alcohol Depend. 2015;154:25-37.
180. Downey LA,King R, Papafotiou K, et al. The effects of cannabis and alcohol on simulated driving: influences of dose and experience. Accid Anal Prev. 2013;50:879-886.
181. Dubois S, Mullen N, Weaver B, Bedard M. The combined effects of alcohol and cannabis on driving: impact on crash risk. Forensic Sci Int. 2015;248:94-100.
182. Sayer G, Ialomiteanu A, Stoduto G, et al. Increased collision risk among drivers who report driving after using alcohol and after using cannabis. Can J Public Health. 2014; 105(1):e92-e93.
183. Beirness DJ, Porath-Waller AJ. Clearing the smoke on cannabis: cannabis use and driving-an update. Ottawa, ON: Canadian Centre on Substance Abuse; 2015.
184. Cannabis, driving and implications for youth. Ottawa, ON: Canadian Centre on Substance Abuse; 2015.
185. Brady JE, Li G. Trends in alcohol and other drugs detected in fatally injured drivers in the United States, 1999-2010. Am J Epidemiol. 2014;179(6):692-699.
186. Berning A, Compton R, Wochinger K. Results of the 2013-2014 National Roadside Survey of Alcohol and Drug Use by Drivers (traffic safety facts research note). Washington, DC: National Highway Traffic Safety Administration; 2015.
187. Couper FJ, Peterson BL. The prevalence of marijuana in suspected impaired driving cases in Washington State. J Anal Toxicol. 2014;38(8):569-574.
188. Berghaus G, Sticht G, Grellner W, Lenz D, Naumann T, Wiesenmuller S. Meta-analysis of empirical studies concerning the effects of medicines and illegal drugs including pharmacokinetics on safe driving. In: Driving Under the Influence of Drugs, Alcohol, and Medicines (DRUID) 6th Framework Programme. Brussels, Belgium: European Commission; 2011:168-176.
189. Verstraete A, Knoche A, Jantos R, et al. Per se limits: methods of defining cut-off values for zero tolerance. In: Driving Under the Influence of Drugs, Alcohol and Medicines (DRUID) 6th Framework Programme. Brussels, Belgium: European Commission; 2011.
190. Vindenes V, Jordbru D, Knapskog AB, et al. Impairment based legislative limits for driving under the influence of non-alcohol drugs in Norway. Forensic Sci Int. 2012;219(1-3):1-11.
191. Wong K, Brady JE, Li G. Establishing legal limits for driving under the influence of marijuana. Inj Epidemiol. 2014;1(1):26.
192. Hall W, Homel R. Reducing cannabis-impaired driving: is there sufficient evidence for drug testing of drivers? Addiction. 2007;102(12):1918-1919.
193. Kraan T, Velthorst E, Koenders L, et al. Cannabis use and transition to psychosis in individuals at ultra-high risk: review and meta-analysis. Psychol Med. 2016;46(4): 673-681.
194. Di Forti M, Iyegbe C, Falcone A, Powell J, Murray R. Vulnerability to cannabis-related psychosis: association with frequency and potency of cannabis use, and interaction with genes regulating dopamine signalling. Lancet. 2014;383(suppl 1):S41.
195. Giordano GN, Ohlsson H, Sundquist K, Sundquist J, Kendler KS. The association between cannabis abuse and subsequent schizophrenia: a Swedish national co-relative control study. Psychol Med. 2015;45(2):407-414.
196. Power RA, Verweij KJ, Zuhair M, et al. Genetic predisposition to schizophrenia associated with increased use of cannabis. Mol Psychiatry. 2014;19(11): 1201-1204.
197. Radhakrishnan R, Wilkinson ST, D'Souza DC. Gone to pot-a review of the association between cannabis and psychosis. Front Psychiatry. 2014;5:54.
198. Degenhardt L, Hall W, Lynskey M, et al. Should burden of disease estimates include cannabis use as a risk factor for psychosis? PLoS Med. 2009;6(9): e1000133.
199. Kedzior KK, Laeber LT. A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population-a meta-analysis of 31 studies. BMC Psychiatry. 2014;14(136):1-22.
200. Lai HM, Sitharthan T. Exploration of the comorbidity of cannabis use disorders and mental health disorders among inpatients presenting to all hospitals in New South Wales, Australia. Am J Drug Alcohol Abuse. 2012; 38(6):567-574.
201. Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Allebeck P. Cannabis use and depression: a longitudinal study of a national cohort of Swedish conscripts. BMC Psychiatry. 2012;12(112):1-7.
202. Shalit N, Shoval G, Shlosberg D, Feingold D, Lev-Ran S. The association between cannabis use and suicidality among men and women: a populationbased longitudinal study. J Affect Disord. 2016;205: 216-224.
203. Gray TR, Eiden RD, Leonard KE, Connors GJ, Shisler S, Huestis MA. Identifying prenatal cannabis exposure and effects of concurrent tobacco exposure on neonatal growth. Clin Chem. 2010;56(9):1442-1450.
204. Day NL, Leech SL, Goldschmidt L. The effects of prenatal marijuana exposure on delinquent behaviors are mediated by measures of neurocognitive functioning. Neurotoxicol Teratol. 2011;33(1):129-136.
205. Sonon KE, Richardson GA, Cornelius JR, Kim KH, Day NL. Prenatal marijuana exposure predicts marijuana use in young adulthood. Neurotoxicol Teratol. 2015;47: 10-15.
206. Willford JA, Chandler LS, Goldschmidt L, Day NL. Effects of prenatal tobacco, alcohol and marijuana exposure on processing speed, visual-motor coordination, and interhemispheric transfer. Neurotoxicol Teratol. 2010; 32(6):580-588.
207. Goldschmidt L, Richardson GA, Larkby C, Day NL. Early marijuana initiation: the link between prenatalmarijuana exposure, early childhood behavior, and negative adult roles. Neurotoxicol Teratol. 2016;58: 40-45.
208. Robison LL, Buckley JD, Daigle AE, et al. Maternal drug use and risk of childhood nonlymphoblastic leukemia among offspring. An epidemiologic investigation implicating marijuana (a report from the Childrens Cancer Study Group). Cancer. 1989;63(10):1904-1911.
209. Grufferman S, Schwartz AG, Ruymann FB, Maurer HM. Parents' use of cocaine and marijuana and increased risk of rhabdomyosarcoma in their children. Cancer Causes Control. 1993;4(3):217-224.
210. Kuijten RR, Bunin GR, Nass CC, Meadows AT. Parental occupation and childhood astrocytoma: results of a case-control study. Cancer Res. 1992;52(4):782-786.
211. Ramsey G. Getting regulation right: assessing Uruguay's historic cannabis initiative. Washington, DC: Washington Office on Latin America; 2016.
212. Hall W, Lynskey M. Evaluating the public health impacts of legalizing recreational cannabis use in the United States. Addiction. 2016;111(10):1764-1773.
213. Pacula RL, Kilmer B, Wagenaar AC, Chaloupka FJ, Caulkins JP. Developing public health regulations for marijuana: lessons from alcohol and tobacco. Am J Public Health. 2014;104(6):1021-1028.
214. Haden M, Emerson B. A vision for cannabis regulation: a public health approach based on lessons learned from the regulation of alcohol and tobacco. Open Med. 2014;8(2):e73-e80.
215. Patton GC, Coffey C, Carlin J, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. BMJ. 2002;325(7374): 1195-1198.
216. Hanson MD, Chen E. Socioeconomic status and health behaviors in adolescence: a review of the literature. J Behav Med. 2007;30(3):263-285.
217. McGee R, Williams S, Poulton R, Moffitt T. A longitudinal study of cannabis use and mental health from adolescence to early adulthood. Addiction. 2000;95(4): 491-503.
218. Lemstra M, Bennett NR, Neudorf C, et al. A meta-analysis of marijuana and alcohol use by socioeconomic status in adolescents aged 10-15 years. Can J Public Health. 2008;99(3):172-177.
219. Kendler KS, Schmitt E, Aggen SH, Prescott CA. Genetic and environmental influences on alcohol, caffeine, cannabis, and nicotine use from early adolescence to middle adulthood. Arch Gen Psychiatry. 2008;65(6): 674-682.
220. Lynskey MT, Heath AC, Nelson EC, et al. Genetic and environmental contributions to cannabis dependence in a national young adult twin sample. Psychol Med. 2002; 32(2):195-207.
221. LaRocca R, Yost J, Dobbins M, Ciliska D, Butt M. The effectiveness of knowledge translation strategies used in public health: a systematic review. BMC Public Health. 2012;12:751.
222. Mitton C, Adair CE, McKenzie E, Patten SB, Waye Perry B. Knowledge transfer and exchange: review and synthesis of the literature. Milbank Q. 2007; 85(4):729-768.
223. Lovatt M, Eadie D, Meier PS, et al. Lay epidemiology and the interpretation of low-risk drinking guidelines by adults in the United Kingdom. Addiction. 2015;110(12):1912-1919.
224. Moss AC, Dyer KR, Albery IP. Knowledge of drinking guidelines does not equal sensible drinking. Lancet. 2009;374(9697):1242.